Postmenopausal Bleeding After Coronavirus Disease 2019 (COVID-19) Vaccination: Vaccine Adverse Event Reporting System
Penelope Strid1, Winston E Abara, Elizabeth Clark
1COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
Insights
Postmenopausal bleeding events reported after COVID-19 vaccination are rare. Verified cases were infrequent, with causes aligning with known postmenopausal bleeding factors, indicating no new safety concerns.
Area of Science:
- Vaccinology
- Gynecology
- Public Health
Background:
- The Vaccine Adverse Event Reporting System (VAERS) monitors vaccine safety in the U.S.
- Postmenopausal bleeding (PMB) is a gynecological concern in women over 50.
- Understanding potential adverse events following COVID-19 vaccination is crucial.
Purpose of the Study:
- To investigate the occurrence of postmenopausal bleeding reports following COVID-19 vaccination.
- To assess the frequency and characteristics of these reported events.
Main Methods:
- Retrospective analysis of U.S. VAERS data from December 13, 2020, to December 13, 2021.
- Identification and verification of postmenopausal bleeding reports among COVID-19 vaccine recipients.
- Calculation of event rates per 1 million vaccinated women aged 50+.
Main Results:
- 554 presumptive PMB reports identified among 711,224 COVID-19 vaccination reports.
- 434 reports were verified, with an estimated rate of 7 verified PMB reports per 1 million vaccinated women (aged 50+).
- Causes of verified PMB were consistent with established etiological factors.
Conclusions:
- Postmenopausal bleeding following COVID-19 vaccination is a rare event.
- The incidence and reported causes do not suggest a novel association.
- Findings support the established safety profile of COVID-19 vaccines regarding PMB.
Abstract:
We identified U.S. reports of postmenopausal bleeding in the VAERS (Vaccine Adverse Event Reporting System) between December 13, 2020, and December 13, 2021. Among 711,224 VAERS reports after coronavirus disease 2019 (COVID-19) vaccination, during our study period, we identified 554 presumptive postmenopausal bleeding reports; 434 were further classified as verified based on data abstracted from reports and medical records, when available. In the United States, by December 14, 2021, 58.8 million women aged 50 years or older had received at least one dose of a COVID-19 vaccine, corresponding to approximately seven verified VAERS postmenopausal bleeding reports per 1 million women aged 50 years or older who received a COVID-19 vaccine. Reports of postmenopausal bleeding after COVID-19 vaccination in VAERS were rare, and causes of postmenopausal bleeding based on medical record review were consistent with known causes of postmenopausal bleeding.
More Related Videos
Related Concept Videos
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
SBAR II: Application of SBAR
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Disorders of the Female Reproductive System


